SUD-001 (片頭痛/Migraine)：医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.1.3 Prognosis 16
3.2 Symptoms 16
3.2.1 Premonitory Phase 17
3.2.2 Aura Phase 17
3.2.3 Headache Phase 18
3.2.4 Postdrome Phase 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Acute Migraine Treatment 22
4.1.2 Preventive Migraine Treatment 23
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25
6 Opportunity and Unmet Need 26
6.1 Overview 26
6.1.1 A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders 27
6.1.2 Lack of Acute Therapies for Patients Unresponsive to Triptan Medication 27
6.1.3 Lack of Diagnostic Tools Causes Misdiagnosis 28
6.1.4 Physician Education 28
6.1.5 Effective and Well-Tolerated Prophylactic Therapies 29
6.2 Unmet Needs Gap Analysis 29
6.2.1 Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication 30
6.2.2 Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies 31
6.2.3 Physician Education 31
6.2.4 Diagnostic Tools 32
7 Pipeline Assessment 33
7.1 Overview 33
7.2 Promising drugs in clinical development 34
8 SUD-001 37
8.1 Overview 37
8.2 Efficacy 38
8.3 Safety 39
8.4 Dosing and Formulation 39
8.5 Potential Clinical Positioning 39
8.6 Potential Commercial Positioning 39
8.7 Pricing and Reimbursement 40
8.8 SWOT Analysis 40
8.9 Forecast 40
9 Appendix 42
9.1 Bibliography 42
9.2 Abbreviations 44
9.3 Methodology 45
9.4 Forecasting Methodology 45
9.4.1 Diagnosed Migraine Patients 45
9.4.2 Percent Drug-treated Patients 45
9.4.3 General Pricing Assumptions 46
9.4.4 Generic Erosion 47
9.4.5 Pricing of Pipeline agents 47
9.5 Physicians and Specialists Included in this Study 48
9.6 Survey of Prescribing Physicians 49
9.7 About the Authors 50
9.7.1 Author 50
9.7.2 Reviewer 50
9.7.3 Global Head of Healthcare 51
9.8 About GlobalData 52
9.9 Disclaimer 52